Biomea Fusion (NASDAQ: BMEA)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-02 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.600 | -0.590 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Biomea Fusion (NASDAQ: BMEA) through any online brokerage.
Other companies in Biomea Fusion’s space includes: Macrogenics (NASDAQ:MGNX), IDEAYA Biosciences (NASDAQ:IDYA), KalVista Pharma (NASDAQ:KALV), Vaxxinity (NASDAQ:VAXX) and 4D Molecular Therapeutics (NASDAQ:FDMT).
The latest price target for Biomea Fusion (NASDAQ: BMEA) was reported by HC Wainwright & Co. on Thursday, June 2, 2022. The analyst firm set a price target for 16.00 expecting BMEA to rise to within 12 months (a possible 17.56% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Biomea Fusion (NASDAQ: BMEA) is $13.61 last updated Today at August 16, 2022, 8:00 PM UTC.
There are no upcoming dividends for Biomea Fusion.
Biomea Fusion’s Q3 earnings are confirmed for Wednesday, November 2, 2022.
There is no upcoming split for Biomea Fusion.
Biomea Fusion is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.